Prevalence of aflatoxin induced p53 mutation at codon 249 (R249s) in hepatocellular carcinoma patients with and without hepatitis B surface antigen (HBsAg).

BACKGROUND A missense mutation in exon 7 (R249S) of the p53 tumor suppressor gene is characteristic of aflatoxin B1 (AFB1) exposure. AFB1 is believed to have a synergistic effect on hepatitis virus B (HBV) carcinogenesis. However, results of studies comparing R249S prevalence among patients are conflicting. The aim of this study was to determine the prevalence of the R249S mutation in hepatocellular carcinoma (HCC) patients with or without positive HBsAg. MATERIALS AND METHODS Paraffin embedded liver tissues were obtained from 124 HCC patients who underwent liver resection and liver biopsy in King Chulalongkorn Memorial Hospital. Restriction fragment length polymorphism (RFLP) was utilized to detect the R249S mutation. Positive results were confirmed by direct sequencing. RESULTS Sixty four (52%) patients were positive for HBsAg and 18 (15%) were anti-HCV positive. 12 specimens tested positive by RFLP. Ten HCC patients (8.1%) were confirmed to be R249S positive by Sanger sequencing (AGG to AGT). Out of these 10, six were HBsAg positive, and out of the remaining 4, two were anti-HCV positive. The R249S prevalence among HCC patients with positive HBsAg was 9.4% compared to 6.7% for HBsAg negative samples. Patients with the R249S mutation were younger (55±10 vs 60±13 year-old) and tended to have a more advanced Edmonson-Steiner grade of HCC, although differences did not reach statistical significance. CONCLUSIONS Our study shows moderate prevalence of aflatoxin B1-related p53 mutation (R249S) in HCC with or without HBsAg. HBsAg positive status was not associated with R249S prevalence.

[1]  P. Hainaut,et al.  Association between HBX status, aflatoxin-induced R249S TP53 mutation and risk of hepatocellular carcinoma in a case-control study from Thailand. , 2013, Cancer letters.

[2]  Zhen Zhang,et al.  Aflatoxin B1-induced hepatocellular carcinoma in developing countries: Geographical distribution, mechanism of action and prevention , 2013, Oncology letters.

[3]  G. Leroux-Roels,et al.  Persistence and immune memory to hepatitis B vaccine 20 years after primary vaccination of Thai infants, born to HBsAg and HBeAg positive mothers , 2012, Human vaccines & immunotherapeutics.

[4]  P. Hainaut,et al.  Aflatoxin-Induced TP53 R249S Mutation in HepatoCellular Carcinoma in Thailand: Association with Tumors Developing in the Absence of Liver Cirrhosis , 2012, PloS one.

[5]  P. Hainaut,et al.  Effects of the TP53 p.R249S mutant on proliferation and clonogenic properties in human hepatocellular carcinoma cell lines: interaction with hepatitis B virus X protein. , 2010, Carcinogenesis.

[6]  P. Khlangwiset,et al.  Costs and efficacy of public health interventions to reduce aflatoxin-induced human disease , 2010, Food additives & contaminants. Part A, Chemistry, analysis, control, exposure & risk assessment.

[7]  Yan Liu,et al.  Global Burden of Aflatoxin-Induced Hepatocellular Carcinoma: A Risk Assessment , 2010, Environmental health perspectives.

[8]  X. Wang,et al.  Cooperation of tumor‐derived HBx mutants and p53‐249ser mutant in regulating cell proliferation, anchorage‐independent growth and aneuploidy in a telomerase‐immortalized normal human hepatocyte‐derived cell line , 2009, International journal of cancer.

[9]  P. Hainaut,et al.  In vitro recapitulating of TP53 mutagenesis in hepatocellular carcinoma associated with dietary aflatoxin B1 exposure. , 2009, Gastroenterology.

[10]  M. Nita,et al.  249 TP53 mutation has high prevalence and is correlated with larger and poorly differentiated HCC in Brazilian patients , 2009, BMC Cancer.

[11]  W. Tsai,et al.  Aflatoxin B1 Exposure, Hepatitis B Virus Infection, and Hepatocellular Carcinoma in Taiwan , 2009, Cancer Epidemiology Biomarkers & Prevention.

[12]  S. Wiangnon,et al.  Incidence of hepatocellular carcinoma in children in Khon Kaen before and after national hepatitis B vaccine program. , 2008, Asian Pacific journal of cancer prevention : APJCP.

[13]  Roger Williams,et al.  Nutrition in end-stage liver disease: principles and practice. , 2008, Gastroenterology.

[14]  Ming-hua Zhu,et al.  Effects of hepatitis B virus on p53 expression in hepatoma cell line SMMU-7721. , 2005, World journal of gastroenterology.

[15]  S. El-Kafrawy,et al.  P53 mutations in hepatocellular carcinoma patients in Egypt. , 2005, International journal of hygiene and environmental health.

[16]  Timothy D Phillips,et al.  Human aflatoxicosis in developing countries: a review of toxicology, exposure, potential health consequences, and interventions. , 2004, The American journal of clinical nutrition.

[17]  H. Whittle,et al.  Ser‐249TP53 mutation in tumour and plasma DNA of hepatocellular carcinoma patients from a high incidence area in the Gambia, West Africa , 2004, International journal of cancer.

[18]  H. Sriplung,et al.  Epidemiology of liver cancer: an overview. , 2004, Asian Pacific journal of cancer prevention : APJCP.

[19]  J. Groopman,et al.  Sensitivity of electrospray ionization mass spectrometry detection of codon 249 mutations in the p53 gene compared with RFLP. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[20]  J. Essigmann,et al.  The aflatoxin B1 formamidopyrimidine adduct plays a major role in causing the types of mutations observed in human hepatocellular carcinoma , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Jack A. Taylor,et al.  Hepatitis B, aflatoxin B(1), and p53 codon 249 mutation in hepatocellular carcinomas from Guangxi, People's Republic of China, and a meta-analysis of existing studies. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[22]  S. Culine,et al.  Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations. , 2000, Cancer research.

[23]  W. Pankow,et al.  Frequent detection of ras and p53 mutations in brush cytology samples from lung cancer patients by a restriction fragment length polymorphism-based "enriched PCR" technique. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  R. Kong,et al.  Mutations at codon 249 of p53 gene in human hepatocellular carcinomas from Tongan, China. , 1997, Mutation research.

[25]  Chien-Jen Chen,et al.  Aflatoxin exposure and risk of hepatocellular carcinoma in Taiwan , 1996, International journal of cancer.

[26]  C. Harris,et al.  An aflatoxin-associated mutational hotspot at codon 249 in the p53 tumor suppressor gene occurs in hepatocellular carcinomas from Mexico. , 1996, Carcinogenesis.

[27]  V. Sheffield,et al.  Low frequency of p53 mutations observed in a diverse collection of primary hepatocellular carcinomas. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[28]  B. Henderson,et al.  Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma , 1992, The Lancet.

[29]  J. Wands,et al.  Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa , 1991, Nature.

[30]  N. Sripathomswat,et al.  Survey of aflatoxin-producing fungi in certain fermented foods and beverages in Thailand , 1981, Mycopathologia.

[31]  P. Tangkijvanich,et al.  Hepatitis B virus genetic variation and TP53 R249S mutation in patients with hepatocellular carcinoma in Thailand. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[32]  M. Kudo,et al.  Needs for hepatocellular carcinoma control policy in the Asia-Pacific region. , 2011, Asian Pacific journal of cancer prevention : APJCP.

[33]  K. Yoo.  Cancer prevention in the Asia Pacific region. , 2010, Asian Pacific journal of cancer prevention : APJCP.

[34]  Tara L. Kieffer,et al.  Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis , 2009 .

[35]  J. Goedert,et al.  249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma. , 2005, Oncogene.

[36]  V. Wiwanitkit,et al.  Aflatoxin contamination of food and food products in Thailand: an overview. , 2003, The Southeast Asian journal of tropical medicine and public health.

[37]  J. Essigmann,et al.  The aflatoxin B(1) formamidopyrimidine adduct plays a major role in causing the types of mutations observed in human hepatocellular carcinoma. , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[38]  M. Greenblatt,et al.  Does aflatoxin B1 play a role in the etiology of hepatocellular carcinoma in the United States? , 1999, Nutrition and cancer.

[39]  H. Zentgraf,et al.  p53 overexpression is frequent in European hepatocellular carcinoma and largely independent of the codon 249 hot spot mutation. , 1994, Oncogene.

[40]  R. Metcalf,et al.  Mutational hotspot in the p53 gene in human hepatocellular carcinomas. , 1991, Nature.

[41]  W. Dupont,et al.  Power and sample size calculations. A review and computer program. , 1990, Controlled clinical trials.